HC Wainwright & Co. Maintains Buy Rating for Biora Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Biora Therapeutics (NASDAQ:BIOR) but lowered its price target from $65.00 to $50.00. Biora Therapeutics' shares are currently trading up 5.45% over the last 24 hours, at $2.29 per share. A move to $50.00 would account for a 2085.03% increase from the current share price.
October 02, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Despite the lowered price target, the maintained Buy rating and the potential for a significant increase in share price could have a positive impact on Biora Therapeutics' stock in the short term.
The maintained Buy rating indicates that HC Wainwright & Co. still sees potential in Biora Therapeutics. Although the price target has been lowered, it still represents a significant increase from the current share price. This could attract investors and drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100